Key Highlights

• Net Debt was $663 million, or 0.57 times normalised EBITDA, a modest level of Leverage for a group of this size.

• Australia is the engine room, generating $10.4 billion of Revenue and $1,034.2 million of normalised EBIT, an increase of 14.9% and 18.3% respectively.

• International revenue grew 33% and EBIT roughly doubled from a smaller base.

• Group EBIT Margin of 10.1% looks high for a wholesaler because the combined group captures franchise, Brand and retail network income as well as distribution margin.

How much difference can a Merger make to a pharmaceutical wholesaler? Sigma Healthcare (ASX:SIG) provided a clear answer on 27 August 2026 with its first full-year result since combining with Chemist Warehouse Group. Revenue for the year ended 30 June 2026 rose 15.5% to $10.8 billion, normalised EBIT rose 20.6% to $1,090.0 million and normalised net profit after tax rose 22.3% to $732.3 million. Chief executive Vikesh Ramsunder said the group is "not simply larger after the merger, it is structurally more encouraging".

The central development: scale, margin and integration

Normalised EBIT margin was 10.1%. Net debt was $663 million, or 0.57 times normalised EBITDA, a modest level of leverage for a group of this size. The final Dividend was 2.0 cents per share fully franked, bringing the full-year dividend to 4.0 cents per share.

Normalised figures exclude items management considers outside underlying trading, such as merger-related costs, so readers should compare them with statutory results in the Appendix 4E.

How the Business makes money

Sigma now has several revenue streams. It wholesales pharmaceuticals and other products to pharmacies, including to the Chemist Warehouse network, runs franchising and brand-licensing relationships such as Amcal and Discount Drug Stores, owns private-label and generic products and operates an international arm. Australia is the engine room, generating $10.4 billion of revenue and $1,034.2 million of normalised EBIT, an increase of 14.9% and 18.3% respectively.

Chemist Warehouse network sales grew 15.9% and like-for-like sales grew 13.4%. The group added 24 Chemist Warehouse stores in Australia, taking the network to 561. Gross margin held at 17.6% despite GLP-1 medicines, which lift sales but dilute margin percentages because they carry lower percentage margins. Own and exclusive-label sales were near $1 billion a year, more than 470 own and exclusive products were launched, and the Wagner generic business grew by more than 30%.

International and synergies

International revenue grew 33% and EBIT roughly doubled from a smaller base. Ireland is now profitable and a UK expansion is underway. The global network approaches 1,000 pharmacies, and the plan includes 19 new international stores in the first half of FY27, including the UK entry.

Merger synergies of $32.6 million were delivered in FY26, against a target of $100 million a year by FY29, with more than half still to come. Synergy targets are management estimates, and delivery typically depends on Supply chain and procurement benefits being realised without disrupting the network.

Sigma also withdrew from a proposed $14 billion Acquisition of UK pharmacy chain Boots that had been announced earlier in 2026, according to Inside Retail.

Outlook and growth pipeline

For the first half of FY27, management expects 13 new Chemist Warehouse stores in Australia and 19 new international stores. The Amcal and Discount Drug Stores brands are being revitalised, with store numbers expected to return to growth in FY27 and a pipeline of 82 outlets.

Management expects GLP-1 sales growth to endure, with flow-on benefits to adjacent categories, but noted it will lap unusually encouraging early-period sales growth, which means growth rates may slow even if Demand holds up.

Sector and competitive position

Australian pharmacy distribution is concentrated, with a few large wholesalers and encouraging regulatory oversight, including the Pharmaceutical Benefits Scheme and pharmacy location rules. Sigma's competitors include other wholesalers and pharmacy banner groups, as well as supermarkets and online retailers in the front-of-shop categories. Its close tie with Chemist Warehouse, the dominant discount pharmacy brand, supports Volume but also creates dependence on one network.

Material risks

- Pharmacy regulation and PBS policy changes, including pricing and dispensing arrangements, which could affect margins.

- GLP-1 dependence: encouraging sales growth boosts revenue but dilutes gross margin percentage, and demand could shift with pricing, supply or policy.

- Integration and synergy delivery: more than half of the $100 million target remains to be achieved.

- Customer concentration: reliance on the Chemist Warehouse network.

- International expansion: entry into the UK and growth in Ireland carry execution and competitive risk.

- Lapping encouraging growth: comparisons become harder in FY27.

Reading the margin and growth trade-offs

Group EBIT margin of 10.1% looks high for a wholesaler because the combined group captures franchise, brand and retail network income as well as distribution margin. That mix is the main reason the merger changed the Earnings profile. It also means that the share of earnings from Chemist Warehouse is large, so changes in that network's growth or terms would matter more than for a traditional wholesaler. Like-for-like growth of 13.4% is unusually encouraging for pharmacy retail, and management itself noted that lapping it will be harder.

Balance sheet and Capital allocation

With net debt at 0.57 times normalised EBITDA, the group has capacity to fund network expansion, integration and potential acquisitions. The decision to withdraw from the proposed Boots transaction suggests management values Balance Sheet discipline over size.

What to monitor next

Investors may watch the half-year result in early 2027, the number of Chemist Warehouse and Amcal openings against the stated first-half targets, progress towards the $100 million synergy target, gross margin trends as GLP-1 volumes grow, and the UK launch. Any news on regulatory changes or major acquisitions would also be material.